14th edition
| Format |
| HYBRID |
December 2nd & 3rd, 2025
IN-PERSON | STRASBOURG
December 8th ,2025
ONLINE MEETINGS
MEDICA is the world’s largest event for the medical sector. Meet us at Medica this year and learn more on BioFIT !
Stand #17A23B at the French Pavillion
Meet us at MEDICA Trade Fair Read More »
Meet the BioFIT team in Frankfurt next week !
November 3-5, 2014
Frankfurt, Germany
*BIO-Europe® is an event produced by EBD Group
Meet us at BIO-Europe 2014 Read More »
One thing everyone agrees on: BioFIT has become the place to be for all stakeholders in Life Sciences
So don’t miss the next edition!
See you next December in Lille, France for the first international partnering event in Europe dedicated to technology transfer and collaborative research in Life Sciences!
Meet the BioFIT team at CPhI in Paris Nord Villepinte on december 8 and 9
Contact us to schedule a meeting
Or Innovations Days on december 6 and 7
Contact us to schedule a meeting
Meet us at CPhI in Paris Read More »
Meet the BioFIT team at BIO SPAIN 2014 at Santiago de Compostela this week.
Meet us at Bio Spain Read More »
Lund University & Eurasante are delighted to launch the 2nd edition of IDEA Summit
After its 1st launch in 2013 in Lund (Sweden), IDEA Summit comes back to Lille (France) on December 2 & 3, 2014.
Unique European event dedicated to collaboration, translational research & technology transfer in diabetes, IDEA Summit aims at:
IDEA Summit offers:
PROGRAM
Plenary Session: 2013-2014 Breakthroughs and innovations in the field of diabetes
A general overview of the last findings in the field of diabetes that have occurred during the last months. The most important events, the major breakthroughs might be summarized in order to answer the question “what has been done in diabetes for the last months?”
Different stakeholders will bear witness to their point of view.
Track 1: What do you expect as a good level of maturity of finding? Too early stage for me guy!
In research collaboration between academia and industries, what is given and what is expected are different and it results that both parts are disappointed. Which type of research fields interest academia, biotech and pharma? Research institutes have to agree with biotech and pharma industries and define what is done by each actor and where does the translation start. Biotech and pharma have to clearly define what they wait from academia in term of patents and results.
In order to organize everything and have good relationships between academia and industries and to accelerate the pace of innovation in diabetes, we have to define and decide what each actor awaits the others, which place takes each stakeholder.
Track 2: Is stratified/personalized/precision medicine one of the paradigm on which we could grind our collective efforts for research in diabetes?
Despite advances in pharmacology, not all patients respond favorably to drugs. Do we need to develop new drug generation? Actually there’s no innovative idea neither new target.
To cross out the lack of future innovative treatments, we need to develop an integrated approach that looks for patients and treatments and to adapt treatments to patient. In that way we don’t need only therapeutics results but also diagnostics results.
We trill try to answer the following questions:
Track 3: Do we need a European joint diabetes research agenda? Who should contribute to it? What should be the goals of this joint research agenda?
Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around specific questions they all want to answer to. Their organization can be different depending on the number of partners involved and the questions addressed. We need to have a global vision of these consortia, to know where they are going and what they miss.
Some questions will be asked to lead the debate:
SPONSORED BY Astra Zeneca, Novo Nordisk and Sanofi
IDEA Summit’s 2nd edition is jointly organized with the 3rd European Genomic Institute for Diabetes (E.G.I.D.) Symposium
On December 2nd, E.G.I.D. Symposium will focus on meta-inflammation in diabetes and its complications.
Save the date – IDEA Summit 2014 Read More »
EVOTEC CEO, Dr. Werner Lanthaler will be speaking at the Plenary Session of BioFIT 2014, on December 2nd at 11am:
Accessing innovation: how to build long term partnerships?
Pharma’s interest on early stage is no longer news in the life sciences industry. In their quest to accessing knowledge, pharma and large biotech got more and more involved in early stage research, either by supporting big consortia or building collaborative research partnerships directly with academia. However, what do we know about the success of such partnerships and big consortia? Have they really worked and what were the outcomes? Where are we today in terms of long-term collaborations? Let’s hear from real experiences, what worked and what didn’t, what lessons have been learned and how have these helped in forging true partnerships.
Dr. Werner Lanthaler’s Biography
Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company’s major corporate milestones including the product approval of Intercell’s Japanese Encephalitis Vaccine, the company’s acquisitions and strategic pharma partnerships, as well as the company’s Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.
He holds a doctorate in economics from Vienna University, earned his Master’s degrees from Harvard University, and holds a degree in Psychology.
New speaker EVOTEC CEO Werner Lanthaler Read More »
You were attending the BIO in San Diego ? Special discount for BIO attendees is extended. Register by July 18th and get 50% off the regular fee for the 2nd attendee to attend BioFIT event.
Please register with the promotional code: BIODISCOUNT
Offer extended: 50% off to attend BioFIT Read More »
Mark Bradley Wilson, Partner at Fulbright & Jaworski LLP will chair 2 linked panel discussions on creative solutions to dealmaking problems and on how to best apply strategic alliance management.
Emerge and happen: creative solutions to difficult problems in dealmaking, on December 3rd, 11am
That things can go wrong in negotiations and partnership is not surprising. However, when you encounter these problems, sometimes creative solutions are needed in order to finally create a mutually beneficial partnership. During this interactive session, the panelists will discuss the common and no so common pitfalls in partnering and negotiations, as well as share their experience on the different stages of negotiations, the difficulties they ran into and the solutions they found.
Make it work and last: how to best apply strategic alliance management, on December 3rd, 2pm
The deal signature is just the beginning of a long road to travel for putting in place a successful partnership. The alliance management is an important piece of the puzzle and if well implemented and understood by both parties, it becomes an effective and invaluable tool in the management of the deal. Let’s discuss how to set it correctly on paper and how to identify the right key licensing terms to the deal and how to manage the partnership in an efficient and rewarding way for both parties.Come meet our speakers of these 2 sessions:
Mark B. WILSON’s biography
Mark Wilson is a partner in Austin, where his practice focuses on all aspects of patent prosecution and enforcement.
Mark’s docket is split among patent counseling, patent prosecution and patent litigation matters, with an emphasis in biotechnology related matters. Mr. Wilson has significant experience in the areas of genetic engineering, gene therapy, molecular biotechnology assays, chemotherapy, drug screening and targeting, animal and plant breeding programs, biomass production, renewable energy, clean energy technologies, organic chemistry, pharmaceutical development and medical devices.
Mark counsels clients regarding intellectual property portfolio development, management and commercialization on a global scale. He is experienced in technology transfer, including both licensing and company formation and funding. Mr. Wilson drafts and reviews licensing, confidentiality and material transfer agreements. He also prepares pre-litigation, infringement, validity, patentability and freedom-to-operate opinions and provides due diligence review of intellectual property to companies and investors.
Mark’s patent prosecution practice includes all aspects of drafting and prosecuting patent applications before the United States Patent and Trademark Office. He also supervises the prosecution of patent applications before many foreign patent offices. In addition, Mr. Wilson is experienced in appeal and interference practice before the Board of Patent Appeals and Interferences.
Mark’s litigation experience includes all phases of discovery and trial in federal district courts, including investigation and formulation of litigation strategy, motion practice, depositions, preparation and examination of witnesses, trials and evidentiary hearings. He has experience in briefing and the development of appellate strategy before the Court of Appeals for the Federal Circuit.
Mark is involved in a wide variety of professional activities. In 2012, he was elected as Deputy Secretary General of FICPI (Federation Internationale des Conseils en Propriete Industrielle), having previously served FICPI as the Assistant Reporter General of the CET. Mark is a frequent presenter at FICPI events and participant in FICPI delegations, visiting government IP offices around the world.
New speaker Mark B. Wilson, Partner at Fulbright & Jaworski Read More »
With more than 1,200 international actors from 35+ countries, such as big pharma, emerging and small biotech, diagnostic companies, pre-seed / seed / Series A investors, as well as professionals from tech transfer, academia and research institutions, BioFIT is the leading partnering event in Europe for technology transfer, academia-industry collaborations and early-stage innovation deals in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed, seed and Series A investment rounds in Life Sciences.
Learn more
Organised by:
WITH THE SUPPORT OF:
INSTITUTIONAL PARTNERS:
"*" indicates required fields
Parc des exposition de Strasbourg – Hall 1
Avenue Herrenschmidt,
67000, Strasbourg, FRANCE
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
WARNING: Some fraudulent companies are supposedly providing the attendees list of BioFIT. And some are passing themselves off as being BioFIT organisation members and asking you to pay. Please note that the BioFIT team will never sell you the BioFIT attendees list and never ask for your bank account details to make you pay for hotel bookings, exhibition fees or others, and certainly not over the phone.Please be extremely vigilant.